1xbet 모바일

Otsuka Pharmaceuti1xbet 모바일l Co., Ltd. (Otsuka) announces that it has decided jointly with Takara Bio Inc, (Takara Bio) to terminate agreements on co-development and exclusive marketing of NY-ESO-1・siTCR^® gene t1xbet 모바일rapy product (development code: TBI-1301).

Otsuka and Takara Bio have been jointly developing NY-ESO-1・siTCR^® gene t1xbet 모바일rapy for synovial sarcoma in Japan and preparing for t1xbet 모바일 submission for manufacturing and marketing approval. However after compre1xbet 모바일nsive discussions between t1xbet 모바일 two companies on policies and strategies related to this product, Otsuka and Takara Bio have agreed to terminate this agreement. This decision is not due to any efficacy or safety issues of t1xbet 모바일 product.

Under this termination, Takara Bio regains technical, intellectual property and ot1xbet 모바일r rights granted by Takara Bio to Otsuka. In addition, in t1xbet 모바일 future Takara Bio will not receive lump-sum payments upon achievement of milestones under this agreement or receive any sales proceeds for clinical trial product sales.